Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.2400 (-1.04%) ($5.2400 - $5.2400) on Wed. Jun. 2, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.09% (three month average) | RSI | 48 | Latest Price | $5.2400(-1.04%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS advances 1% a day on average for past five trading days. | Weekly Trend | ADMS advances 1.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Rotation from growth to value for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) TLT(88%) KWEB(61%) ARKG(45%) EEM(45%) VWO(41%) | Factors Impacting ADMS price | ADMS will decline at least -2.045% in a week (0% probabilities). XLE(-54%) USO(-38%) OIH(-28%) XLY(-4%) XLU(-8%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.045% (StdDev 4.09%) | Hourly BBV | -0.4 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.23(0.19%) | 10 Day Moving Average | $5.18(1.16%) | 20 Day Moving Average | $5.15(1.75%) | To recent high | -10.7% | To recent low | 4.6% | Market Cap | $148m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |